Corpus overview


Overview

MeSH Disease

Leukopenia (23)

Fever (18)

Infections (14)

Cough (14)

Lymphopenia (13)


Human Phenotype

Leukopenia (23)

Fever (18)

Lymphopenia (13)

Cough (13)

Pneumonia (8)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 23
    records per page




    Clinical characteristics of 134 convalescent patients with COVID-19 in Guizhou, China

    Authors: Siqin Zhang; Lin Liu; Bin Yang; Rou Li; Jianhua Luo; Jing Huang; Yanjun Long; Ying Huang; Jianping Zhou; Yan Zha; Xiangyan Zhang

    doi:10.21203/rs.3.rs-41986/v1 Date: 2020-07-13 Source: ResearchSquare

    Background: Previous studies have focused on the clinical characteristics of hospitalized patients with the novel 2019 coronavirus disease MESHD (COVID-19). Limited data are available for convalescent patients. This study aimed to evaluate the clinical characteristics of discharged COVID-19 patients.Methods: In this retrospective study, we extracted data for 134 convalescent patients with COVID-19 in Guizhou Provincial Staff Hospital from February 15 to March 31, 2020. Cases were analyzed on the basis of demographic, clinical, and laboratory data as well as radiological features. Results: Of 134 convalescent patients with COVID-19, 19 (14.2%) were severe cases, while 115 (85.8%) were non-severe cases. The median patient age TRANS was 33 years (IQR, 21.8 to 46.3), and the cohort included 69 men and 65 women. Compared with non-severe cases, severe patients were older and had more chronic comorbidities, especially hypertension MESHD hypertension HP, diabetes, and thyroid disease MESHD (P<0.05). Leukopenia MESHD Leukopenia HP was present in 32.1% of the convalescent patients and lymphocytopenia was present in 6.7%, both of which were more common in severe patients. 48 (35.8%) of discharged patients had elevated levels of alanine aminotransferase, which was more common in adults TRANS than in children TRANS (40.2% vs 13.6%, P=0.018). A normal chest CT was found in 61 (45.5%) patients during rehabilitation. Severe patients had more ground-glass opacity, bilateral patchy shadowing, and fibrosis MESHD. No significant differences were observed in the positive rate of IgG and/or IgM antibodies SERO between severe and non-severe patients.Conclusion: Leukopenia MESHD Leukopenia HP, lymphopenia MESHD lymphopenia HP, ground-glass opacity, and fibrosis MESHD are common in discharged severe COVID-19 patients, and liver injury is common in discharged adult TRANS patients. We suggest physicians develop follow-up treatment plans based on the different clinical characteristics of convalescent patients. 

    SEROPREVALENCE SERO AND CLINICAL SPECTRUM OF SARS-CoV-2 INFECTION MESHD IN THE FIRST VERSUS THIRD TRIMESTER OF PREGNANCY

    Authors: Francesca Crovetto; Fatima Crispi; Elisa Llurba; Francesc Figueras; Maria Dolores Gomez-Roig; Eduard Gratacos

    doi:10.1101/2020.06.17.20134098 Date: 2020-06-19 Source: medRxiv

    Introduction: Case registries of pregnant women diagnosed with coronavirus disease MESHD (COVID-19) by polymerase chain reaction (PCR) have reported that the majority experienced mild infection MESHD, but up to 9% may require critical care. Most COVID-19 cases published were in the third trimester of pregnancy, which could reflect reporting bias, higher risk of infection TRANS risk of infection TRANS infection MESHD or increased disease MESHD severity in late pregnancy. Seroprevalence SERO studies may allow reliable estimates of the susceptibility to infection MESHD and clinical spectrum since they include asymptomatic TRANS and mild infections MESHD not tested for PCR. We evaluated the seroprevalence SERO and clinical presentation of severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) infection MESHD in pregnant women in the first and third trimester. Methods: The study was approved by the Institutional Review Board at each institution and informed consent was obtained. We recruited 874 consecutive pregnancies attending for first trimester screening (10-16 weeks of gestation, n=372) or delivery (n=502) from April 14 to May 5. All women were interviewed with a structured questionnaire for COVID-19 symptoms two months prior to sampling. SARS-CoV-2 IgG and IgM/IgA antibodies were tested SERO (COVID-19 VIRCLIA Monotest, Vircell Microbiologist, Spain; reported sensitivity SERO 70% IgG and 89% IgM/IgA, and specificity 89% and 99% respectively). Indeterminate results were re-tested (VITROS Immunodiagnostic Products Anti-SARS-CoV2 Total Tests, Ortho Clinical Diagnostics, USA; 100% sensitivity SERO and specificity) and re-classified as positive or negative. Women with COVID-19 were diagnosed and managed according to standard protocols and guidelines3,4. Statistical differences were tested using the {chi}2 test or Student t-test as appropriate (p<0.05). Results: A total of 125 of 874 women (14.3%) were positive for either IgG or IgM/IgA SARS-CoV-2 antibodies SERO, 54/372 (14.5%) in the first and 71/502 (14.1%) in the third trimester. A total of 75/125 (60%) reported no symptoms of COVID-19 in the past 2 months, whereas 44 (35.2%) reported one or more symptoms, of which 31 (24.8%) had at least 3 symptoms or anosmia HP and 8 (6.4%) dyspnea MESHD dyspnea HP. Overall, 7 women (5.6%) were admitted for persistent fever MESHD fever HP despite paracetamol and dyspnea MESHD dyspnea HP, of which 3 had signs of pneumonia MESHD pneumonia HP on chest radiography. All 3 had criteria for severity (bilateral chest condensation, respiratory rate>30 and leukopenia MESHD leukopenia HP) and required oxygen support but not critical care or mechanical ventilation, and they were all discharged well. The rates of symptomatic infection MESHD, hospital admission or dyspnea MESHD dyspnea HP were significantly higher in third trimester women (Table and Figure). Discussion: The 14.3% seroprevalence SERO of SARS-COV-2 in pregnant women in this study was substantially larger than the contemporary rates of PCR positive cases (0.78%) reported for women 20-40y in Barcelona. The data confirm that COVID-19 is asymptomatic TRANS in the majority of pregnant women6 and illustrate the value of seroprevalence SERO studies to capture the high proportion of asymptomatic TRANS or mild infections MESHD. In this study, none of the 125 pregnant women with SARS-CoV-2 infection MESHD required critical care as compared to 9% reported in cases diagnosed with PCR. However, the proportion of infections MESHD with symptoms or dyspnea MESHD dyspnea HP was remarkably higher in the third trimester, and these results are in line with COVID-19 registries, reporting that 81% of hospitalized women were in late pregnancy or peripartum. These results provide reassuring information that, even in settings with a high prevalence SERO, SARS-CoV-2 infection MESHD in pregnancy mostly presents with asymptomatic TRANS or mild clinical forms. The susceptibility to infection MESHD seemed to be the same in the first and the third trimesters of gestation. The data further suggest that, as with other respiratory viruses, COVID-19 could be more severe and require increased surveillance in late pregnancy. These findings should be confirmed and extended with larger consecutive prevalence SERO studies in pregnancy.

    Afebrile Patients with Severe Acute Respiratory Syndrome MESHD Coronavirus 2 Infection MESHD have a Longer Viral Positivity Duration: A Retrospective Analysis of 125 Patients

    Authors: Rui Ding; Rugang Zhao; Wen Xie; Ying Fan; Ligai Liu; Ying Cao; Cheng Cheng; JingJing Wang; Qi Wang; Yanbin Wang; Ting Zhang; Minghui LI

    doi:10.21203/rs.3.rs-36961/v1 Date: 2020-06-19 Source: ResearchSquare

    Background: A pandemic of severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) is on-going. Clinical characters of afebrile cases infected with SARS-CoV-2 remain poorly understood and informations are limited on the duration of SARS-CoV-2 viral positivity.Methods: We performed a single-center retrospective study of 125 patients with SARS-CoV-2 infection MESHD in Beijing Ditan Hospital, Capital Medical University from January 26 to March 15, 2020. Differences were compared among patients with/without fever MESHD fever HP. Risk factors for the duration of SARS-CoV-2 viral positivity were evaluated.Results: A total of 125 patients with positive SARS-CoV-2 test were enrolled, including 38 afebrile patients and 87 febrile patients. On admission, a total of 35 (28%) patients had leukopenia MESHD leukopenia HP, 41 (32.8%) had lymphopenia MESHD lymphopenia HP and 6 (4.8%) had thrombocytopenia MESHD thrombocytopenia HP. 73 patients (58.4%) had a loss of T lymphocytes and 96 patients (76.8%) had decreased CD4+T lymphocytes. Compared with febrile cases, afebrile patients had a significantly higher white blood SERO cell count (P = 0.001), total lymphocytes (P < 0.001), platelet count (P < 0.001), T lymphocytes (P = 0.013) and CD8+ T lymphocytes (P = 0.002). The median SARS-CoV-2 viral positivity duration of these 125 patients was 14 days (IQR, 10-30 days) and for febrile and afebrile group were 12 days (IQR, 9-23 days) and 23 days (IQR, 11-30 days) respectively. Multivariate Cox regression results showed that the fever MESHD fever HP [hazard ratio (HR) = 0.497, P = 0.006], young age TRANS (HR = 0.965, P = 0.018), and higher count of platelet (HR = 4.555, P = 0.034) were the predominant risk factor for the SARS-CoV-2 viral positivity duration.Conclusion: The SARS-CoV-2 virial positivity duration of the afebrile group was significantly longer than that in the febrile group. Fever MESHD Fever HP, young age TRANS and a higher count of platelet were the independent protective factors for a shorter SARS-CoV-2 RNA positivity duration.

    Laboratory findings in coronavirus disease MESHD 2019 (COVID-19) patients: a comprehensive systematic review and meta-analysis

    Authors: Mohammad Karimian; Amirreza Jamshidbeigi; Gholamreza Badfar; Milad Azami

    doi:10.1101/2020.06.07.20124602 Date: 2020-06-08 Source: medRxiv

    Background: In early December 2019, the first patient with COVID-19 pneumonia MESHD pneumonia HP was found in Wuhan, Hubei Province, China. Recent studies have suggested the role of primary laboratory tests in addition to clinical symptoms for suspected patients, which play a significant role in the diagnosis of COVID-19. Therefore, the present study was conducted to evaluate laboratory findings in COVID-19 patients. Material and methods: The present meta-analysis was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. This protocol is registered with the code CRD42019145410 in PROSPERO International Database. Results: Finally, 52 studies involving 5490 patients with COVID-19 entered the meta-analysis process. The prevalence SERO of leukopenia MESHD leukopenia HP, lymphopenia MESHD lymphopenia HP, elevated c-reactive protein (CRP), elevated erythrocyte sedimentation rate HP (ESR), elevated serum SERO amyloid A, elevated ferritin was estimated to be 20.9% (95%CI: 17.9-24.3), 51.6% (95%CI: 44.0-59.1), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 74.7% (95%CI: 50.0-89.7), and 72.6% (95%CI: 58.1-83.5), respectively. The prevalence SERO of elevated interleukin-6 was 59.9% (95%CI: 48.2-70.5), CD3 was 68.3% (95%CI: 50.1-82.2), reduced CD4 was 62.0% (95%CI: 51.1-71.6), reduced CD8 was 42.7% (95%CI: 32.2-53.9). The prevalence SERO of elevated troponin-I was 20.6% (95%CI: 9.0-40.5), elevated creatine kinase-MB (CKMB) was 14.7% (95%CI: 7.1-28.0), elevated brain natriuretic peptide (BNP) was 48.9% (95%CI: 30.4-67.7), elevated blood SERO urea nitrogen was 13.1% (95%CI: 6.6-24.4),, elevated creatinine was 7.2% (95%CI: 4.4-11.8), elevated lactate dehydrogenase (LDH) was 53.1% (95%CI: 43.6-62.4), hyperglycemia MESHD hyperglycemia HP was 41.1% (95% CI: 28.2-55.5), elevated total bilirubin was 48.9% (95%CI: 30.4-67.7), reduced albumin was 54.7% (95%CI: 38.1-70.2), reduced pre-albumin was 49.0% (95%CI: 26.6-71.8), and reduced PT was 53.1% (95% CI: 43.6-62.4), and D-dimer was 44.9% (95%CI: 31.0-59.6). Conclusion This study provides a comprehensive description of laboratory characteristics in patients with COVID-19. The results show that lymphopenia MESHD lymphopenia HP, elevated CRP, elevated ESR, elevated ferritin, elevated serum SERO amyloid A, elevated BNP, reduced albumin, reduced pre-albumin, reduced CD3, reduced CD4, reduced CD8, elevated D-dimer, reduced PT, elevated interleukin-2, elevated interleukin-6, elevated LDH and hyperglycemia MESHD hyperglycemia HP are the common findings at the time of admission.

    Leukopenia MESHD Leukopenia HP of Asymptomatic TRANS COVID-19 Infections MESHD under 18 Years Old in Recovery Stage

    Authors: Wei Zhang; Youshu Yuan Sr.; Zhengqiao Yang Sr.; Jianxia Fu Sr.; Yun Zhang Sr.; Ming Ma; Weidong Wu Jr.; Hourong Zhou Jr.

    doi:10.1101/2020.05.21.20074682 Date: 2020-05-26 Source: medRxiv

    Objectives In December, 2019, a type of novel coronavirus which was designated novel coronavirus 2019 (2019-nCoV) by World Health Organization (WHO) occurred in Wuhan, Hubei, China. The epidemiological and clinical characteristics of those patients under 18 years old in the recovery stage are limited. To compare the difference of epidemiological and clinical characteristics of COVID-19 involving 25 patients under 18 years old in recovery stage between confirmed and asymptomatic infections MESHD asymptomatic TRANS. Methods Retrospective, single-center cohort study of COVID-19 involving 25 patients under 18 years old in the recovery stage at Guizhou Provincial Staff Hospital in Guiyang, China, from January 29, to March 31, 2020; final date of follow-up was April 22. Epidemiological, demographic, clinical, laboratory, radiological, and treatment data were collected and analyzed. Epidemiological and clinical characteristics of confirmed COVID-19 infections and asymptomatic MESHD asymptomatic TRANS infections MESHD were compared. Results Among the 25 COVID infections MESHD under 18 years old, 16 (64%) were mild or moderate confirmed cases TRANS, and 9 (36%) were asymptomatic TRANS. The shortest treatment period was 6 days, the longest 26 days, and the average treatment period 14 days. Four cases (44.4%) had visited Wuhan or had a living story in the city. There were 9 (100%) asymptomatic TRANS cases were familial cluster outbreak, with an average infection MESHD number was 6 cases among all families. The number of asymptomatic TRANS COVID-19 infections MESHD with leukopenia MESHD leukopenia HP were significantly more than confirmed cases TRANS (p=0.04). Conclusions Leukopenia MESHD Leukopenia HP mostly occurred in asymptomatic TRANS COVID-19 infections MESHD under 18 years old compared with the confirmed patients.

    Leukopenia MESHD Leukopenia HP of Asymptomatic TRANS COVID-19 Infections MESHD under 18 Years Old in Recovery Stage

    Authors: Wei Zhang; Youshu Yuan; Zhengqiao Yang; Jinxia Fu; Yun Zhang; Ming Ma; Weidong Wu; Hourong Zhou

    doi:10.21203/rs.3.rs-29855/v1 Date: 2020-05-19 Source: ResearchSquare

    Background In December, 2019, a type of novel coronavirus which was designated novel coronavirus 2019 (2019-nCoV) by World Health Organization (WHO) occurred in Wuhan, Hubei, China. The epidemiological and clinical characteristics of those patients under 18 years old in the recovery stage are limited. To compare the difference of epidemiological and clinical characteristics of COVID-19 involving 25 patients under 18 years old in recovery stage between confirmed and asymptomatic infections MESHD asymptomatic TRANS.Methods Retrospective, single-center cohort study of COVID-19 involving 25 patients under 18 years old in the recovery stage at Guizhou Provincial Staff Hospital in Guiyang, China, from January 29, to March 31, 2020; final date of follow-up was April 22. Epidemiological, demographic, clinical, laboratory, radiological, and treatment data were collected and analyzed. Epidemiological and clinical characteristics of confirmed COVID-19 infections and asymptomatic MESHD asymptomatic TRANS infections MESHD were compared.Results Among the 25 COVID infections MESHD under 18 years old, 16 (64%) were mild or moderate confirmed cases TRANS, and 9 (36%) were asymptomatic TRANS. The shortest treatment period was 6 days, the longest 26 days, and the average treatment period 14 days. Four cases (44.4%) had visited Wuhan or had a living story in the city. There were 9 (100%) asymptomatic TRANS cases were familial cluster outbreak, with an average infection MESHD number was 6 cases among all families. The number of asymptomatic TRANS COVID-19 infections’ Leukopenia MESHD Leukopenia HP were significantly more than confirmed cases TRANS (p = 0.04).Conclusions Leukopenia MESHD Leukopenia HP mostly occurred in asymptomatic TRANS COVID-19 infections MESHD under 18 years old compared with the confirmed patients.

    Comparison of initial HRCT features of COVID-19 pneumonia MESHD pneumonia HP and other viral pneumonias MESHD pneumonias HP

    Authors: Yilong Huang; Yuanming Jiang; Li Wu; Wenfang Yi; Jiyao Ma; Peng Wang; Ying Xie; Zhipeng Li; Xiang Li; Minchang Hong; Jialong Zhou; Chuwei Duan; Yunhui Yang; Wei Zhao; Feng Yuan; Dan Han; Bo He

    doi:10.21203/rs.3.rs-29527/v1 Date: 2020-05-17 Source: ResearchSquare

    Background: Multicenter retrospective comparison of the first high-resolution computed tomography (HRCT) findings of coronavirus disease MESHD 2019 (COVID-19) and other viral pneumonias MESHD pneumonias HP.Methods: We retrospectively collected clinical and imaging data from 254 cases of confirmed TRANS viral pneumonia MESHD pneumonia HP in 20 hospitals in Yunnan Province, China, from March 1, 2015, to March 15, 2020. According to the virus responsible for the pneumonia MESHD pneumonia HP, the pneumonias MESHD pneumonias HP were divided into non-COVID-19 (133 cases) and COVID-19 (121 cases). The non-COVID-19 pneumonias MESHD pneumonias HP included 3 types: cytomegalovirus (CMV) (31 cases), influenza A virus (82 cases), and influenza B virus (20 cases). The differences in the basic clinical characteristics, lesion distribution, location and imaging signs among the four viral pneumonias MESHD pneumonias HP were analyzed and compared.Results: Fever MESHD Fever HP and cough MESHD cough HP were the most common clinical symptoms of the four viral pneumonias MESHD pneumonias HP. Compared with the COVID-19 patients, the non-COVID-19 patients had higher proportions of fatigue MESHD fatigue HP, sore throat, expectorant and chest tightness HP (all p<0.000). In addition, in the CMV pneumonia MESHD pneumonia HP patients, the proportion of patients with combined acquired immunodeficiency syndrome MESHD immunodeficiency HP syndrome (AIDS) and leukopenia MESHD leukopenia HP were high (all p<0.000). Comparisons of the imaging findings of the four viral pneumonias MESHD pneumonias HP showed that pulmonary lesions of COVID-19 were more likely to occur in the peripheral and lower lobes of both lungs, while those of CMV pneumonia MESHD pneumonia HP were diffusely distributed. Compared with the non-COVID-19 pneumonias MESHD pneumonias HP, COVID-19 pneumonia MESHD pneumonia HP was more likely to present as ground-glass opacity (GGO), intralobular interstitial thickening HP, vascular thickening and halo sign (all p<0.05). In addition, in the early stage of COVID-19, extensive consolidation, fibrous stripes, subpleural lines, crazy-paving pattern, tree-in-bud HP, mediastinal lymphadenectasis, pleural thickening HP and pleural effusion MESHD pleural effusion HP were rare (all p<0.05).Conclusion: The HRCT findings of COVID-19 pneumonia MESHD pneumonia HP and other viral pneumonias MESHD pneumonias HP overlapped significantly, but many important differential imaging features could still be observed.

    Severe Acute Respiratory Syndrome MESHD Coronavirus 2 Infection MESHD in Patients Living with Human Immunodeficiency HP Virus: Case Reports and Review of the Literature

    Authors: Liping Chen; Fang Xiao; Li Cao; Meng Xie; Yue Wen; Zhicheng Zhang; Qiang Ding; Wei Yan; Dean Tian; Ge Wang

    doi:10.21203/rs.3.rs-28578/v1 Date: 2020-05-11 Source: ResearchSquare

    Background: Novel coronavirus pneumonia MESHD pneumonia HP (COVID-19) outbreak caused by severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) has rapidly spread over the globe. The knowledge about SARS-CoV-2 infection MESHD in immunocompromised patients was limited. Case presentation: We presented here two human immunodeficiency HP virus (HIV)-infected cases with laboratory confirmed COVID-19 and clinically confirmed COVID-19, respectively. The patients both presented with fever MESHD fever HP at illness onset and patchy shadows in radiological images of lungs. Laboratory findings revealed leukopenia MESHD leukopenia HP, lymphopenia MESHD lymphopenia HP and positive anti-HIV antibody SERO. The younger case had a moderate course and was discharged after a 28-day hospitalization. However, the elder case with multiple comorbidities developed dyspnea MESHD dyspnea HP and died on the fourth day after admission. Conclusions: Combining our data with two case reports, we summarize that disease MESHD course varies in HIV-infected patients with COVID-19. More attention should be paid to the management of these patients. Whether there is any difference about clinical characteristics and prognosis of COVID-19 between HIV-infected and non-HIV infected patients, remains to be further investigated.

    Clinical and CT manifestations of coronavirus disease MESHD 2019 (COVID-19): comparison of suspected cases of COVID-19 in isolation and non-COVID-19 pneumonia MESHD pneumonia HP in a single-center study conducted in Beijing, China

    Authors: Heng Liu; Weihua Li; Lei Zhang; Bing Liu; Chaoying Qi; Wei Fan; Pei Feng; Jingjing Pan; Fengyuan Man

    doi:10.21203/rs.3.rs-27288/v1 Date: 2020-05-06 Source: ResearchSquare

    Background: The clinical and CT manifestations of COVID-19 pneumonia MESHD pneumonia HP and non-COVID-19 pneumonia MESHD pneumonia HP in the same period have not been compared in detail. The purpose of this study is to analyze the clinical and CT manifestations of COVID-19 pneumonia MESHD pneumonia HP and perform a comparison of those isolated patients for presumed COVID-19 infection MESHD and of non-COVID-19 pneumonia MESHD pneumonia HP in the same period.Methods: 173 patients with pneumonia MESHD pneumonia HP from January 1, 2020 to March 20, 2020 were retrospectively enrolled and classified into three groups: patients with COVID-19 pneumonia MESHD pneumonia HP (Group I, N=4), patients in hospital-isolation for presumed COVID-19 pneumonia MESHD pneumonia HP (Group Ⅱ, N=5), and patients with non-COVID-19 pneumonia MESHD pneumonia HP (Group III, N=163). Clinical symptoms, laboratory test results and CT imaging features were compared among three groups.Results: Fever MESHD Fever HP and cough MESHD cough HP were the most common clinical symptoms in the three groups. 30/163 (18.4%) patients were asymptomatic TRANS in Group III. Leukopenia MESHD Leukopenia HP, lymphocytopenia, and elevated C-reactive protein was identified in 1 (25%), 1 (25%), and 1 (25%) patient in Group I; 1 (20%), 1 (20%), and 2 (40%) patients in Group II; 10/157 (6.4%), 33/157(21.0%), and 94/136 (69.1%) patients in Group III. Demarcated GGO/mixed GGO, ill-defined GGO/mixed GGO, consolidation, centrilobular nodule, tree-in bud opacity, bilateral involvement, peripheral distribution, posterior part/lower lobe predilection was observed in 3/4 (75%), 2/4 (50%), 4/4 (100%), 2/4 (50%), 0, 3/4 (75%), 3/4 (75%), and 2/4 (50%) patients, respectively in Group I; 1/5 (20%), 5/5 (100%), 4/5 (80%), 4/5 (80%), 3/5 (60%), 4/5 (80%), 2/5 (40%), and 3/5 (60%) patients in Group Ⅱ; 1/163 (0.6%), 87/163 (54.3%), 115/163 (70.6%), 117/163 (71.8%), 95/163 (58.3%), 52/163 (31.9%), 9/163 (5.5%), and 9/163 (5.5%) patients in Group III, respectively.Conclusions: Demarcated GGO and consolidation prefer the diagnosis of COVID-19 pneumonia MESHD pneumonia HP, whereas ill-defined GGO and consolidation, centrilobular nodule surrounded by GGO, and tree-in-bud opacity are preferred for non-COVID-19 pneumonia MESHD pneumonia HP. chest CT has potential in early identification of COVID-19 and implementation of isolation for appropriate case.

    Hydroxychloroquine-Induced Stevens-Johnson Syndrome MESHD in COVID-19: A rare Case Report

    Authors: Lotfollah Davoodi; Hamed Jafarpour; Armaghan Kazeminejad; Eissa Soleymani; Zahra Akbari; Alireza Razavi

    doi:10.21203/rs.3.rs-26196/v1 Date: 2020-04-29 Source: ResearchSquare

    Background: The international outbreak of respiratory illness termed coronavirus disease MESHD 2019 (COVID-19) began in December 2019 that has affected more than 0.8 million individuals. To date, there are no specific therapeutic agents for coronavirus infections MESHD. One of the drugs that have an effective role in improving the condition of patients with COVID-19 is hydroxychloroquine (HCQ). This drug is not a definitive treatment for this disease MESHD and has a supportive role. Like all medications, HCQ has side effects and may occur in COVID-19 patients. Stevens-Johnson syndrome MESHD caused by HCQ is very rare.Case presentation: A 42-year-old woman, presented with fever MESHD fever HP and dry cough MESHD cough HP in the past two days to her family physician. Lab tests revealed elevated lactate dehydrogenase (LDH, 648 units/liter (U/L)), C-reactive protein level (CRP, 52 milligrams/Liter (mg/L), normal: <10 mg/L), aspartate aminotransferase (AST, 59 U/L, normal: 10-40 U/L), thrombocytopenia MESHD thrombocytopenia HP, and leukopenia MESHD leukopenia HP. Mild bilateral patchy ground-glass opacity was seen in lung CT-Scan. Due to COVID-19 pandemic and clinical findings, the nasopharyngeal swab test was done and SARS-CoV-2 nucleic acid was detected by RT-PCR. HCQ 200 mg twice daily was started. After two days, the patient presented with a pruritic erythematous maculopapular rash and flat atypical targets that started from the distal of upper extremities and rapidly, involved the entire body, and torn blisters MESHD which were only be seen as ulcers MESHD on orolabial area. The Nikolsky sign was positive. Due to the likelihood of a drug reaction, HCQ was discontinued, and COVID-19 treatment was changed to lopinavir/ritonavir (LPV/RTV) 400 mg twice daily. Finally, she was discharged after five days with nonpruritic scalded skin on the distal of upper extremities. Conclusions: It is worth noting that although HCQ appears to be safe and has mild side effects, however, the boundary between therapeutic and toxic doses is narrow and severe disorders of their use can life-threatening. One of the side effects of HCQ is SJS caused by the drug, and given the worldwide pandemic of COVID-19 and the increasing need for this drug, we need to be careful about its use in order to control and manage the side effects of this drug. 

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.